Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 12, Issue 4, 2002, Pages 247-257

  Faingezicht, Idis ^a   Avila Aguerro, Maria Luisa ^a   Cervantes, Yolanda ^b   Fourneau, Marc ^c   Clemens, Sue Ann Costa ^d  

^a HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^b GLAXOSMITHKLINE   (Mexico)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d Estrada dos Bandeirantes   (Brazil)

Author keywords

Diphtheria tetanus pertussis vaccine; Haemophilus influenzae; Hepatitis B; Vaccination; Vaccines, combined

Indexed keywords

ANTIBODY; ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

CHILD HEALTH; DISEASE CONTROL; HEPATITIS; VACCINATION;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL MENINGITIS; BIRTH; BRONCHIOLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COSTA RICA; DIPHTHERIA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEEDING DISORDER; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INJECTION; INJECTION PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPOTONIA; PERTUSSIS; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; TETANUS; VACCINATION;

COSTA RICA;

EID: 0036806580     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1020-49892002001000005     Document Type: Article

References (34)

1. World Health Organization. The World Health Report 2000 - Health Systems: Improving Performance. Geneva: WHO; 2000.
2. Fauci A. Infectious diseases: Considerations for the 21st century. Clin Infect Dis 2001; 32 (5):675-685.
3. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children - United States, 1900-1998. MMWR 1999;48:243-248.
4. World Health Organization. The World Health Report 1999: Making a Difference. Geneva: WHO; 1999.
5. World Health Organization. Vaccines and Biologicals Annual Report 1998. Geneva: WHO; 1999.
6. World Health Organization. The World Health Report 1998: Life in the 21st Century - A Vision for All. Geneva: WHO; 1998.
7. Clemens SA, da Fonseca JC, Azevedo T, Cavalcanti A, Silveira TR, Castillo MC, et al. Soroprevalência para hepatite A e hepatite B em quatro centros no Brasil. Rev Soc Bras Med Trop 2000;33:1-10.
8. Silveira TR, da Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JL, et al. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica 1999;6:378-383.
9. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children after ten years of mass vaccination in Taiwan. JAMA 1996;276:906-908.
10. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. NEJM 1997; 336:1855-1859.
11. World Health Organization. Expanded Programme on Immunization. Global Advisory Group-part 1. Wkly Epidemiol Rec 1992;67:11-15.
12. World Health Organization. The Children's Vaccine Initiative and the Global Programme for Vaccines and Immunization. Recommendations from the Special Advisory Group of Experts. Wkly Epidemiol Rec 1996;71:261-268.
13. Peltola H. Haemophilus influenzae type b disease and vaccination in Latin America and the Caribbean. Pediatr Infect Dis J 1997;16(8):750-757.
14. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13(2):302-317.
15. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-1197.
16. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996;15:216-222.
17. Pan American Health Organization. Haemophilus Influenzae Type B Vaccine in the Americas [Internet site]. Available from: http://www.paho.org/English/HVP/HVI/hvp_hib. htm. Accessed 1 October 2001.
18. World Health Organization. Global Programme for Vaccines and Immunization (GPV). The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998;73(10):64-68.
19. Usonis V, Bakasenas V, Willems P, Bock H. Evaluation of the immunogenicity and reactogenicity of a new combined diphtheria, tetanus, whole-cell Bordetella pertussis and hepatitis B and Haemophilus influenzae type b (DTPw-HBV/Hib) vaccine in children at 3, 4.5, and 6 months of age. Acta Med Lituanica 1999;6(3):187-191.
20. Diez-Delgado J, Dal-Re R, Llorente M, Gonzalez A, Lopez J. Hepatitis B component does not interfere with the immune response to diphtheria, tetanus, and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 1997;15(12-13):1418-1422.
21. Prikazsky V, Bock HL. Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4 and 5 months of age in Slovakia. Int J Clin Pract 2001;55(3):156-161.
22. Chiu HH, Huang LM, Lee PI, Safary A, Lee CY. Diphtheria, tetanus and whole cell pertussis vaccine combined with hepatitis B vaccines: A comparison of two doses (10 mcg and 5 mcg). Pediatr Infect Dis J 1998;17:206-211.
23. Bravo L, Carlos J, Gatchalian S, Borja-Tabora C, Bibera G, Willems P, et al. The new DTPw-HBV/Hib combination vaccine can be used at the WHO schedule with a monovalent dose of hepatitis B vaccine at birth. Southeast Asian J Trop Med Public Health 1998;29(4):772-778.
24. Riedemann S, Reinhardt G, Jara J, Rios R, Wenzel MS, Willems P, et al. Reactogenicity and immunogenicity of a diphtheria-tetanuspertussis-hepatitis B and Haemophilus type b vaccine (DTPwHBV/Hib) versus separately administered DTPwHBV and Hib vaccines in infants. J Paediatr Child Health 1997;33(suppl 1):121.
25. Win KM, Aye M, Htay-Htay H, Safary A, Bock H. Comparison of separate or mixed administration of DTPwHBV and Hib vaccines: Immunogenicity and reactogenicity profiles. Int J Infect Dis 1997;2(2):79-84.
26. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45(RR12):1-35.
27. Pan American Health Organization. Introduction of Haemophilus Influenzae Type B Vaccine in the Americas [Internet site]. Available from: http://www.paho.org/English/HVP/ HVI/hvp_hib_text.htm. Accessed 1 October 2001.
28. Combination vaccines for childhood immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 1999;48:1-13.
29. Pan American Health Organization. Mexico introduces pentavalent vaccine. EPI Newsletter 1999;21(4):8.
30. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 1998;16(9-10):921-927.
31. Castillo de Febres O, Decker MD, Estopinan M, Bordones G, Edwards KM. Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1994;13:635-639.
32. Levine OS, Granoff DM, Lagos R, Fritzell B, Levine MM. Factors associated with superior antibody response to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 1997;15(3):325-328.
33. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981;68:650-660.
34. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-355.